NxStage Medical (NASDAQ:NXTM) : Zacks Investment Research ranks NxStage Medical (NASDAQ:NXTM) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.86, which indicates as a Buy.
NxStage Medical (NASDAQ:NXTM) : 5 Wall Street analysts covering NxStage Medical (NASDAQ:NXTM) believe that the average level the stock could reach for the short term is $23.6. The maximum price target given is $30 and the minimum target for short term is around $16, hence the standard deviation is calculated at $5.41.
For the current week, the company shares have a recommendation consensus of Buy.
NxStage Medical (NASDAQ:NXTM): stock turned positive on Tuesday. Though the stock opened at $20.24, the bulls momentum made the stock top out at $20.9 level for the day. The stock recorded a low of $19.91 and closed the trading day at $20.7, in the green by 6.37%. The total traded volume for the day was 1,799,902. The stock had closed at $19.46 in the previous days trading.
In an insider trading activity, Turk Joseph E Jr, (President) of Nxstage Medical, Inc., unloaded 1,500 shares at an average price of $17.89 on May 12, 2016. The total amount of the transaction was worth $26,835, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
NxStage Medical, Inc. is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product, the System One, is a small, portable, easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One, In-Center and Services.